• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer

ZEG Berlin GmbH

Zentrum für Epidemiologie und Gesundheitsforschung

  • Home
  • Expertise
    • Real-World Evidence
    • Non-interventional study design
    • Post-authorization safety studies
    • Post-authorization efficacy studies
    • Cohort studies
    • Case-control studies
    • Medical Devices
    • Data collection instruments
  • Services
    • RWE Services
    • Crisis Management
    • Consulting
    • Data Management and Biostatistics
    • Medical Writing
    • Study Management
    • Quality Assurance
    • Pharmacovigilance
  • Library & News
    • News/Conferences
    • Publications
  • PROs
    • Menopause Rating Scale
      • Menopause Rating Scale (MRS) – Languages
    • Aging Male Symptoms Scale
      • AMS – properties as an outcome measure
      • AMS – properties as a screening tool
    • Quality of Sexual Function Scale
      • Quality of Sexual Function Scale
    • Short Term Hormone Effect Scale
      • Short Term Hormone Effect Scale
    • Research team
  • About Us
    • Who We Are
      • Management Board
      • Executive Team
      • Project Management Team
    • History
    • Careers
    • Data Protection Information
  • Contact

AMS – properties as an outcome measure

Detection of treatment effect

A summary of the results of the first clinical study where the AMS scale was applied as an outcome measure for testosterone treatment in patients with androgen deficiency is provided below20. Overall, the AMS was able to detect changes in outcome measurements.

On average, the AMS recorded an absolute improvement of symptoms during treatment of 15 points. This was equivalent to an average of 32% of the baseline score.

The relative improvement increased with the degree of severity of symptoms at baseline; 11% relative improvement, 24%, 31%, and 39% improvement in males with little, mild, moderate, and severe complaints at baseline, respectively. Overall, a positive treatment effect was detectable with the AMS scale in men with moderate or even mild symptoms.The next figure shows the capacity of the AMS scale to detect therapeutic efficiency from another angle: the comparison with the norm values of the population 5. The level of complaints in elderly patients before therapy is shifted toward a higher degree of severity (higher AMS total score).

After 12 weeks of testosterone treatment, the frequency distribution of patients with a certain severity of complaints became similar to the distribution in the general population of aging males. This is re-assuring and indicates that comparisons with norm values could be helpful for interpreting results of intervention studies.

Prediction of expert assessment

The AMS was also able to predict the independent judgment of the urologists regarding the therapeutic effect. Treating urologists assessed the effectiveness of the hormone treatment in the afore-mentioned intervention study – without prior knowledge of AMS results.

Urologist’s opinions regarding treatment efficiency were divided into two categories: effective and not effective. AMS results were similarly grouped and their correlation assessed.  The positive predictive value was 89%, the negative predictive value 59%, sensitivity (correct prediction of a positive assessment by the physician) 96% and specificity (correct prediction of a negative assessment by the physician) 30% 20.

In other words, the change of the AMS score fits well with a positive judgment of the physician concerning therapy efficiency, however, does not predict a negative therapy assessment of the physician well. This means, using the total AMS score as a criterion, it would result in a high positive predictive value but a less satisfactory negative predictive value, very high sensitivity but low specificity.

A subsequent publication from 2006 confirmed this finding. The conclusion of the authors was that the AMS scale showed a convincing ability to measure treatment effects on quality of life across the full range of severity of complaints. Effect modification by other variables at baseline was not observed. In addition, results of the scale could predict the subjective clinical expert opinion on the treatment efficiency.


5. Heinemann LAJ, Saad F, Heinemann K, DoMinh Thai. Can results of the AMS scale predict those of screening scales for androgen deficiency? Aging Male 2004; Submitted for publication.

20. Morley JE, Charlton E, Patrick P, Kaiser FE, Cadeau P, McCready D, Perry III HM. Validation of a screening questionnaire for androgen deficiency in aging males. Metabolism 2000; 49:1239-42.

sidebar

Expertise

  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
    • Aging Male Symptoms Scale
    • Menopause Rating Scale
    • Scale for Quality of Sexual Function
    • Short Term Hormone Effect Scale
    • Research team
  • Data collection instruments

sidebar-alt

Footer

ZEG Berlin

Berlin Center for Epidemiology and Health Research

Invalidenstraße 115
10115 Berlin
Germany

Contact Us

Expertise

  • Real-World Evidence
  • Non-interventional study design
  • Post-authorization safety studies
  • Post-authorization efficacy studies
  • Cohort studies
  • Case-control studies
  • Medical Devices
  • Patient Reported Outcomes (PROs)
  • Data collection instruments

Services

  • Crisis Management
  • Consulting
  • Data Management and Biostatistics
  • Medical Writing
  • Study Management
  • Quality Assurance
  • Pharmacovigilance

ENCePP

We are a partner centre of the ENCePP scientific network which is coordinated by the European Medicines Agency. We are dedicated to excellence in research by adhering to the ENCePP Guide on Methodological Standards and promoting scientific independence and transparency. We register studies in the ENCePP E-Register of Studies, a publicly accessible resource for the registration of pharmacoepidemiological and pharmacovigilance studies.

General Data Protection Regulation

With a view to the introduction of the GDPR/EUDSGVO we are glad to present our newupdated privacy policy . The updated description are stored under “about us” and then “privacy policy/GDPR”. Further translation for study participants will follow contemporary.

© 2011–2025 ZEG Berlin

Impressum

Website by Laura Yeffeth.